Guangfeng Li

Prof. Dr. Guangfeng Li

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2024 in Materials Today Bio
Verified
Journal Article
Open access
PSPeiran Song
Peiran Song
DZDongyang Zhou
Dongyang Zhou
FWFuxiao Wang
Fuxiao Wang
GLGuangfeng Li
Guangfeng Li
LBLong Bai
Long Bai
JSJiacan Su
Jiacan Su
Programmable biomaterials are distinguished by their ability to adjust properties and functions on demand, in a periodic, reversible, or sequential manner. This contrasts with traditional biomaterials, which undergo irreversible, uncontrolled changes. This review synthesizes key advances in programmable biomaterials, examining their design principles, functionalities and applications in bone regeneration. It charts the transition from traditional to programmable biomaterials, emphasizing their enhanced precision, safety and control, which are critical from clinical and biosafety standpoints. We then classify programmable biomaterials into six types: dynamic nucleic acid-based biomaterials, electrically responsive biomaterials, bioactive scaffolds with programmable properties, nanomaterials for targeted bone regeneration, surface-engineered implants for sequential regeneration and stimuli-responsive release materials. Each category is analyzed for its structural properties and its impact on bone tissue engineering. Finally, the review further concludes by highlighting the challenges faced by programmable biomaterials and suggests integrating artificial intelligence and precision medicine to enhance their application in bone regeneration and other biomedical fields.

7 June 2024 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
BHBiaotong Huang
Biaotong Huang
GLGuangfeng Li
Guangfeng Li
LCLie-Hu Cao
Lie-Hu Cao
SWShaozhen Wu
Shaozhen Wu
YZYuanwei Zhang
Yuanwei Zhang
JSJiacan Su
Jiacan Su

25 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WZWeidong Zhang
Weidong Zhang
GLGuangfeng Li
Guangfeng Li
JZJinbo Zhang
Jinbo Zhang
XCXiao Chen
Xiao Chen
JSJiacan Su
Jiacan Su
FZFengjin Zhou
Fengjin Zhou
Osteoarthritis (OA) is a degenerative disease of the joints characterized by cartilage damage and severe pain. Despite various pharmacological and surgical interventions, current therapies fail to halt OA progression, leading to high morbidity and an economic burden. Thus, there is an urgent need for alternative therapeutic approaches that can effectively address the underlying pathophysiology of OA. Extracellular Vesicles (EVs) derived from mesenchymal stromal cells (MSCs) represent a new paradigm in OA treatment. MSC-EVs are small membranous particles released by MSCs during culture, both in vitro and in vivo. They possess regenerative properties and can attenuate inflammation, thereby promoting cartilage healing. Importantly, MSC-EVs have several advantages over MSCs as cell-based therapies, including lower risks of immune reactions and ethical issues. Researchers have recently explored different strategies, such as modifying EVs to enhance their delivery, targeting efficiency, and security, with promising results. This article reviews how MSC-EVs can help treat OA and how they might work. It also briefly discusses the benefits and challenges of using MSC-EVs and talks about the possibility of allogeneic and autologous MSC-EVs for medical use.